Inflammation meets metabolic disease: Gut feeling mediated by GLP-1

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Zietek, Tamara ^a   Rath, Eva ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Diabetes mellitus; Enteroendocrine cells; ER stress; Glucagon like peptide 1; Incretins; Inflammation; Inflammatory bowel disease; Microbiota

Indexed keywords

CHOLECYSTOKININ; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; SHORT CHAIN FATTY ACID; SODIUM GLUCOSE COTRANSPORTER; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; ENTEROENDOCRINE CELL; GASTROINTESTINAL MOTILITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTESTINE FLORA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN UNFOLDING; REVIEW; TASTE BUD; UNFOLDED PROTEIN RESPONSE;

EID: 84966709097     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00154     Document Type: Review

References (209)

1. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status in children and adolescents: United States, 2005-2008. NCHS Data Brief (2010) (51):1-8
2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med (2007) 356(3):213-5. doi:10.1056/NEJMp068177
3. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 3(7):390-407. doi:10.1038/ncpgasthep0528
4. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ, et al. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med (2004) 1(1):e27. doi:10.1371/journal.pmed.0010027
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature (2006) 444(7121):860-7. doi:10.1038/nature05485
6. Nielsen ST, Janum S, Krogh-Madsen R, Solomon TP, Møller K. The incretin effect in critically ill patients: a case-control study. Crit Care (2015) 19(1):402. doi:10.1186/s13054-015-1118-z
7. Steven S, Hausding M, Kröller-Schön S, Mader M, Mikhed Y, Stamm P, et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol (2015) 110(2):6. doi:10.1007/s00395-015-0465-x
8. Rath E, Haller D. Inflammation and cellular stress: a mechanistic link between immune-mediated and metabolically driven pathologies. Eur J Nutr (2011) 50(4):219-33. doi:10.1007/s00394-011-0197-0
9. Brestoff JR, Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell (2015) 161(1):146-60. doi:10.1016/j.cell.2015.02.022
10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 259(5091):87-91. doi:10.1126/science.7678183
11. Clavel T, Desmarchelier C, Haller D, Gérard P, Rohn S, Lepage P, et al. Intestinal microbiota in metabolic diseases: from bacterial community structure and functions to species of pathophysiological relevance. Gut Microbes (2014) 5(4):544-51. doi:10.4161/gmic.29331
12. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis (2007) 13(9):1153-64. doi:10.1002/ibd.20174
13. Helander HF, Fandriks L. Surface area of the digestive tract-revisited. Scand J Gastroenterol (2014) 49(6):681-9. doi:10.3109/00365521.2014.898326
14. Worthington JJ. The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease. Biochem Soc Trans (2015) 43(4):727-33. doi:10.1042/BST20150090
15. Zietek T, Daniel H. Intestinal nutrient sensing and blood glucose control. Curr Opin Clin Nutr Metab Care (2015) 18(4):381-8. doi:10.1097/MCO.0000000000000187
16. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology (2012) 153(7):3054-65. doi:10.1210/en.2011-2170
17. Egerod KL, Engelstoft MS, Grunddal KV, Nøhr MK, Secher A, Sakata I, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology (2012) 153(12):5782-95. doi:10.1210/en.2012-1595
18. Sykaras AG, Demenis C, Cheng L, Pisitkun T, Mclaughlin JT, Fenton RA, et al. Duodenal CCK cells from male mice express multiple hormones including ghrelin. Endocrinology (2014) 155(9):3339-51. doi:10.1210/en.2013-2165
19. Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol (2016) 78:277-99. doi:10.1146/annurev-physiol-021115-105439
20. Nakamura E, Hasumura M, Uneyama H, Torii K. Luminal amino acid-sensing cells in gastric mucosa. Digestion (2011) 83(Suppl 1):13-8. doi:10.1159/000323399
21. Choi S, Lee M, Shiu AL, Yo SJ, Halldén G, Aponte GW. GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells. Am J Physiol Gastrointest Liver Physiol (2007) 292(5):G1366-75. doi:10.1152/ajpgi.00516.2006
22. Oya M, Kitaguchi T, Pais R, Reimann F, Gribble F, Tsuboi T. The G protein-coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells. J Biol Chem (2013) 288(7):4513-21. doi:10.1074/jbc.M112.402677
23. Wang JH, Inoue T, Higashiyama M, Guth PH, Engel E, Kaunitz JD, et al. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats. J Pharmacol Exp Ther (2011) 339(2):464-73. doi:10.1124/jpet.111.184788
24. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, Daly K, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A (2007) 104(38):15075-80. doi:10.1073/pnas.0706678104
25. Aranias T, Grosfeld A, Poitou C, Omar AA, Le Gall M, Miquel S, et al. Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation. J Nutr Sci (2015) 4:e22. doi:10.1017/jns.2015.11
26. Behrens M, Meyerhof W. Gustatory and extragustatory functions of mammalian taste receptors. Physiol Behav (2011) 105(1):4-13. doi:10.1016/j.physbeh.2011.02.010
27. Jeon TI, Zhu B, Larson JL, Osborne TF. SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice. J Clin Invest (2008) 118(11):3693-700. doi:10.1172/JCI36461
28. Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, et al. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr (2012) 95(1):78-83. doi:10.3945/ajcn.111.021543
29. Ford HE, Peters V, Martin NM, Sleeth ML, Ghatei MA, Frost GS, et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. Eur J Clin Nutr (2011) 65(4):508-13. doi:10.1038/ejcn.2010.291
30. Steinert RE, Frey F, Töpfer A, Drewe J, Beglinger C. Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br J Nutr (2011) 105(9):1320-8. doi:10.1017/S000711451000512X
31. Vegezzi G, Anselmi L, Huynh J, Barocelli E, Rozengurt E, Raybould H, et al. Diet-induced regulation of bitter taste receptor subtypes in the mouse gastrointestinal tract. PLoS One (2014) 9(9):e107732. doi:10.1371/journal.pone.0107732
32. Latorre R, Huynh J, Mazzoni M, Gupta A, Bonora E, Clavenzani P, et al. Expression of the bitter taste receptor, T2R38, in enteroendocrine cells of the colonic mucosa of overweight/obese vs. lean subjects. PLoS One (2016) 11(2):e0147468. doi:10.1371/journal.pone.0147468
33. Lee RJ, Cohen NA. Taste receptors in innate immunity. Cell Mol Life Sci (2015) 72(2):217-36. doi:10.1007/s00018-014-1736-7
34. Nguyen AT, Mandard S, Dray C, Deckert V, Valet P, Besnard P, et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes (2014) 63(2):471-82. doi:10.2337/db13-0903
35. Wichmann A, Allahyar A, Greiner TU, Plovier H, Lundén Gö, Larsson T, et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 14(5):582-90. doi:10.1016/j.chom.2013.09.012
36. Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep (2014) 9(4):1202-8. doi:10.1016/j.celrep.2014.10.032
37. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res (2013) 33(4):213-23. doi:10.3109/10799893.2013.802805
38. Palazzo M, Balsari A, Rossini A, Selleri S, Calcaterra C, Gariboldi S, et al. Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion. J Immunol (2007) 178(7):4296-303. doi:10.4049/jimmunol.178.7.4296
39. Selleri S, Palazzo M, Deola S, Wang E, Balsari A, Marincola FM, et al. Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. Int Immunol (2008) 20(8):961-70. doi:10.1093/intimm/dxn055
40. Bogunovic M, Davé SH, Tilstra JS, Chang DT, Harpaz N, Xiong H, et al. Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol (2007) 292(6):G1770-83. doi:10.1152/ajpgi.00249.2006
41. Zhang WJ, Duan JZ, Lei N, Xing H, Shao Y, Yang GB. Cellular bases for interactions between immunocytes and enteroendocrine cells in the intestinal mucosal barrier of rhesus macaques. Cell Tissue Res (2012) 350(1):135-41. doi:10.1007/s00441-012-1464-y
42. Moran GW, Leslie FC, Levison SE, Worthington J, McLaughlin JT. Enteroendocrine cells: neglected players in gastrointestinal disorders? Ther Adv Gastroenterol (2008) 1(1):51-60. doi:10.1177/1756283X08093943
43. Ingersoll SA, Ayyadurai S, Charania MA, Laroui H, Yan Y, Merlin D. The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol (2012) 302(5):G484-92. doi:10.1152/ajpgi.00477.2011
44. Hu Y, Smith DE, Ma K, Jappar D, Thomas W, Hillgren KM. Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm (2008) 5(6):1122-30. doi:10.1021/mp8001655
45. Wuensch T, Ullrich S, Schulz S, Chamaillard M, Schaltenberg N, Rath E, et al. Colonic expression of the peptide transporter PEPT1 is downregulated during intestinal inflammation and is not required for NOD2-dependent immune activation. Inflamm Bowel Dis (2014) 20(4):671-84. doi:10.1097/01.MIB.0000443336.71488.08
46. Dalmasso G, Nguyen HT, Ingersoll SA, Ayyadurai S, Laroui H, Charania MA, et al. The PepT1-NOD2 signaling pathway aggravates induced colitis in mice. Gastroenterology (2011) 141(4):1334-45. doi:10.1053/j.gastro.2011.06.080
47. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med (2011) 17(11):1481-9. doi:10.1038/nm.2513
48. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology (2009) 150(2):580-91. doi:10.1210/en.2008-0726
49. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology (1996) 137(7):2968-78. doi:10.1210/endo.137.7.8770921
50. Yusta B, Baggio LL, Koehler J, Holland D, Cao X, Pinnell LJ, et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes (2015) 64(7):2537-49. doi:10.2337/db14-1577
51. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med (2005) 202(8):1023-9. doi:10.1084/jem.20042397
52. Rubin DC, Zhang H, Qian P, Lorenz RG, Hutton K, Peters MG. Altered enteroendocrine cell expression in T cell receptor alpha chain knock-out mice. Microsc Res Tech (2000) 51(2):112-20. doi:10.1002/1097-0029(20001015)51:2<112::AID-JEMT2>3.0.CO;2-D
53. O'Hara JR, Skinn AC, MacNaughton WK, Sherman PM, Sharkey KA. Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon. Cell Microbiol (2006) 8(4):646-60. doi:10.1111/j.1462-5822.2005.00657.x
54. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia (2010) 53(4):730-40. doi:10.1007/s00125-009-1643-x
55. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science (1993) 261(5120):466-9. doi:10.1126/science.8101391
56. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev (1998) 161:55-70. doi:10.1111/j.1600-065X.1998.tb01571.x
57. Han JM, Patterson SJ, Speck M, Ehses JA, Levings MK. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. J Immunol (2014) 192(2):623-9. doi:10.4049/jimmunol.1302181
58. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol (2010) 9:17. doi:10.1186/1475-2840-9-17
59. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, et al. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol (2013) 12:117. doi:10.1186/1475-2840-12-117
60. Hattori A, Kawamura I, Yamada Y, Kanamori H, Aoyama T, Ushikoshi H, et al. Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study. BMJ Open (2013) 3(9):e003201. doi:10.1136/bmjopen-2013-003201
61. Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes (2014) 63(10):3221-9. doi:10.2337/db14-0100
62. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care (2009) 32(Suppl 2):S223-31. doi:10.2337/dc09-S315
63. Azoulay L. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care (2015) 38(6):951-3. doi:10.2337/dc15-0347
64. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 33(2):428-33. doi:10.2337/dc09-1499
65. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med (2014) 370(9):794-7. doi:10.1056/NEJMp1314078
66. Lovshin JA, Zinman B. Blood pressure-lowering effects of incretin-based diabetes therapies. Can J Diabetes (2014) 38(5):364-71. doi:10.1016/j.jcjd.2014.05.001
67. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One (2014) 9(5):e97554. doi:10.1371/journal.pone.0097554
68. El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA. Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic pathway. Life Sci (2015) 126:81-6. doi:10.1016/j.lfs.2015.01.030
69. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One (2011) 6(9):e25269. doi:10.1371/journal.pone.0025269
70. Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol (2014) 20(40):14821-30. doi:10.3748/wjg.v20.i40.14821
71. Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol (2015) 308(8):F878-87. doi:10.1152/ajprenal.00590.2014
72. Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement (2014) 10(1 Suppl):S47-54. doi:10.1016/j.jalz.2013.12.009
73. Iwai T, Sawabe T, Tanimitsu K, Suzuki M, Sasaki-Hamada S, Oka J. Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. J Neurosci Res (2014) 92(4):446-54. doi:10.1002/jnr.23335
74. Chen CY, Tsai CY. From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis? Rheumatology (Oxford) (2014) 53(2):205-12. doi:10.1093/rheumatology/ket255
75. Gou S, Zhu T, Wang W, Xiao M, Wang XC, Chen ZH. Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kappaB in mice. Int Immunopharmacol (2014) 22(2):498-504. doi:10.1016/j.intimp.2014.07.010
76. van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab (2013) 15(7):593-606. doi:10.1111/dom.12050
77. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis (2012) 221(2):375-82. doi:10.1016/j.atherosclerosis.2011.12.039
78. He L, Wong CK, Cheung KK, Yau HC, Fu A, Zhao HL, et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabetes Investig (2013) 4(4):382-92. doi:10.1111/jdi.12063
79. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia (2012) 55(9):2456-68. doi:10.1007/s00125-012-2592-3
80. Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H, et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes (2014) 63(11):3637-46. doi:10.2337/db14-0263
81. Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci (2007) 81(4):272-9. doi:10.1016/j.lfs.2007.04.040
82. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2013) 98(6):2553-61. doi:10.1210/jc.2012-4288
83. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci (2009) 30(11):600-7. doi:10.1016/j.tips.2009.08.003
84. Reinhold D, Bank U, Bühling F, Lendeckel U, Faust J, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology (1997) 91(3):354-60. doi:10.1046/j.1365-2567.1997.d01-2258.x
85. Zhao Y, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. J Diabetes (2014) 6(1):21-9. doi:10.1111/1753-0407.12063
86. Vora KA, Porter G, Peng R, Cui Y, Pryor K, Eiermann G, et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol (2009) 10:19. doi:10.1186/1471-2172-10-19
87. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 62(11):1543-52. doi:10.1016/j.metabol.2013.07.001
88. Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther (2014) 28(5):425-32. doi:10.1007/s10557-014-6539-4
89. Gonçalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrósio AF, et al. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta (2014) 1842(9):1454-63. doi:10.1016/j.bbadis.2014.04.013
90. Fenkci S, Rota S, Sabir N, Sermez Y, Guclu A, Akdag B. Relationship of serum interleukin-6 and tumor necrosis factor alpha levels with abdominal fat distribution evaluated by ultrasonography in overweight or obese postmenopausal women. J Investig Med (2006) 54(8):455-60. doi:10.2310/6650.2006.06010
91. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry (2010) 68(10):930-41. doi:10.1016/j.biopsych.2010.06.012
92. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104(4):487-501. doi:10.1016/S0092-8674(01)00237-9
93. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 51(1):37-43. doi:10.1136/gut.51.1.37
94. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature (1997) 389(6651):610-4. doi:10.1038/39335
95. Gagnon J, Sauvé M, Zhao W, Stacey HM, Wiber SC, Bolz SS, et al. Chronic exposure to TNFalpha impairs secretion of glucagon-like peptide-1. Endocrinology (2015) 156(11):3950-60. doi:10.1210/en.2015-1361
96. Tsukahara T, Watanabe K, Watanabe T, Yamagami H, Sogawa M, Tanigawa T, et al. Tumor necrosis factor alpha decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease. Am J Pathol (2015) 185(1):185-96. doi:10.1016/j.ajpath.2014.09.010
97. Lehrskov-Schmidt L, Lehrskov-Schmidt L, Nielsen ST, Holst JJ, Møller K, Solomon TP. The effects of TNF-alpha on GLP-1-stimulated plasma glucose kinetics. J Clin Endocrinol Metab (2015) 100(4):E616-22. doi:10.1210/jc.2014-4244
98. Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2009) 21(3):283-8. doi:10.1097/MEG.0b013e328325d42b
99. Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol (2012) 25(1):37-44
100. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. Pediatr Res (2008) 64(6):673-6. doi:10.1203/PDR.0b013e318186dde2
101. Chen CY, Tsai CY, Lee PC, Lee SD. Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin. Curr Pharm Des (2013) 19(10):1956-64. doi:10.2174/1381612811319100014
102. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 16(5):448-57. doi:10.1038/ni.3153
103. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum (2011) 63(3):609-21. doi:10.1002/art.30158
104. Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One (2014) 9(12):e114195. doi:10.1371/journal.pone.0114195
105. Herder C, Haastert B, Müller-Scholze S, Koenig W, Thorand B, Holle R, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes (2005) 54(Suppl 2):S11-7. doi:10.2337/diabetes.54.suppl_2.S11
106. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab (1997) 82(12):4196-200. doi:10.1210/jcem.82.12.4450
107. Holmes AG, Mesa JL, Neill BA, Chung J, Carey AL, Steinberg GR, et al. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J Endocrinol (2008) 198(2):367-74. doi:10.1677/JOE-08-0113
108. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schaüble M, et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem (2006) 281(11):7060-7. doi:10.1074/jbc.M509782200
109. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A (2013) 110(40):16199-204. doi:10.1073/pnas.1306799110
110. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes (2009) 58(11):2525-35. doi:10.2337/db08-1261
111. Chakraborti CK. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes (2015) 6(15):1296-308. doi:10.4239/wjd.v6.i15.1296
112. Pais R, Zietek T, Hauner H, Daniel H, Skurk T. RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. Am J Physiol Gastrointest Liver Physiol (2014) 307(3):G330-7. doi:10.1152/ajpgi.00329.2013
113. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol (2007) 8(7):519-29. doi:10.1038/nrm2199
114. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem (2005) 74:739-89. doi:10.1146/annurev.biochem.73.011303.074134
115. Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol (2006) 4(11):e374. doi:10.1371/journal.pbio.0040374
116. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep (2006) 7(9):880-5. doi:10.1038/sj.embor.7400779
117. Bertolotti A, Wang X, Novoa I, Jungreis R, Schlessinger K, Cho JH, et al. Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. J Clin Invest (2001) 107(5):585-93. doi:10.1172/JCI11476
118. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med (2008) 5(3):e54. doi:10.1371/journal.pmed.0050054
119. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 134(5):743-56. doi:10.1016/j.cell.2008.07.021
120. Martinon F, Chen X, Lee AH, Glimcher LH. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol (2010) 11(5):411-8. doi:10.1038/ni.1857
121. Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, Sonenberg N, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol (2004) 24(23):10161-8. doi:10.1128/MCB.24.23.10161-10168.2004
122. Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ (2004) 11(4):372-80. doi:10.1038/sj.cdd.4401378
123. Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol (2006) 26(8):3071-84. doi:10.1128/MCB.26.8.3071-3084.2006
124. Burkart A, Shi X, Chouinard M, Corvera S. Adenylate kinase 2 links mitochondrial energy metabolism to the induction of the unfolded protein response. J Biol Chem (2011) 286(6):4081-9. doi:10.1074/jbc.M110.134106
125. Pouyssegur J, Shiu RP, Pastan I. Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell (1977) 11(4):941-7. doi:10.1016/0092-8674(77)90305-1
126. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell (2010) 140(6):900-17. doi:10.1016/j.cell.2010.02.034
127. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell (2001) 7(6):1165-76. doi:10.1016/S1097-2765(01)00265-9
128. Huang CJ, Haataja L, Gurlo T, Butler AE, Wu X, Soeller WC, et al. Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab (2007) 293(6):E1656-62. doi:10.1152/ajpendo.00318.2007
129. Kharroubi I, Ladrière L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology (2004) 145(11):5087-96. doi:10.1210/en.2004-0478
130. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res (2006) 47(12):2726-37. doi:10.1194/jlr.M600299-JLR200
131. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (2004) 306(5695):457-61. doi:10.1126/science.1103160
132. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell (2001) 7(6):1153-63. doi:10.1016/S1097-2765(01)00264-7
133. Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka TA, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem (2005) 280(1):847-51. doi:10.1074/jbc.M411860200
134. Back SH, Scheuner D, Han J, Song B, Ribick M, Wang J, et al. Translation attenuation through eIF2alpha phosphorylation prevents oxidative stress and maintains the differentiated state in beta cells. Cell Metab (2009) 10(1):13-26. doi:10.1016/j.cmet.2009.06.002
135. Silva AM, Wang D, Komar AA, Castilho BA, Williams BR. Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner. J Biol Chem (2007) 282(14):10164-71. doi:10.1074/jbc.M609996200
136. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res (2001) 61(16):6213-8
137. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137-40. doi:10.1126/science.1128294
138. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 118(1):316-32. doi:10.1172/JCI32752
139. Erbay E, Babaev VR, Mayers JR, Makowski L, Charles KN, Snitow ME, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med (2009) 15(12):1383-91. doi:10.1038/nm.2067
140. Cao SS, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson JE, et al. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology (2013) 144(5):989.e-1000.e. doi:10.1053/j.gastro.2013.01.023
141. Zhao F, Edwards R, Dizon D, Afrasiabi K, Mastroianni JR, Geyfman M, et al. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. Dev Biol (2010) 338(2):270-9. doi:10.1016/j.ydbio.2009.12.008
142. Heijmans J, van Lidth de Jeude JF, Koo BK, Rosekrans SL, Wielenga MC, van de Wetering M, et al. ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep (2013) 3(4):1128-39. doi:10.1016/j.celrep.2013.02.031
143. Vasu S, Moffett RC, McClenaghan NH, Flatt PR. Differential molecular and cellular responses of GLP-1 secreting L-cells and pancreatic alpha cells to glucotoxicity and lipotoxicity. Exp Cell Res (2015) 336(1):100-8. doi:10.1016/j.yexcr.2015.05.022
144. Cummings BP, Bettaieb A, Graham JL, Kim J, Ma F, Shibata N, et al. Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech (2013) 6(2):443-56. doi:10.1242/dmm.010421
145. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 118(2):229-41. doi:10.1016/j.cell.2004.07.002
146. Worthington JJ, Samuelson LC, Grencis RK, McLaughlin JT. Adaptive immunity alters distinct host feeding pathways during nematode induced inflammation, a novel mechanism in parasite expulsion. PLoS Pathog (2013) 9(1):e1003122. doi:10.1371/journal.ppat.1003122
147. Harrison E, Lal S, McLaughlin JT. Enteroendocrine cells in gastrointestinal pathophysiology. Curr Opin Pharmacol (2013) 13(6):941-5. doi:10.1016/j.coph.2013.09.012
148. Bermudez R, Vigliano F, Quiroga MI, Nieto JM, Bosi G, Domeneghini C. Immunohistochemical study on the neuroendocrine system of the digestive tract of turbot, Scophthalmus maximus (L.), infected by Enteromyxum scophthalmi (Myxozoa). Fish Shellfish Immunol (2007) 22(3):252-63. doi:10.1016/j.fsi.2006.05.006
149. Wang H, Steeds J, Motomura Y, Deng Y, Verma-Gandhu M, El-Sharkawy RT, et al. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut (2007) 56(7):949-57. doi:10.1136/gut.2006.103226
150. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World J Gastroenterol (2012) 18(42):6070-5. doi:10.3748/wjg.v18.i42.6070
151. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Dig Dis Sci (2012) 57(12):3154-9. doi:10.1007/s10620-012-2249-6
152. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 39(5):596-604. doi:10.1038/ng2032
153. Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflamm Bowel Dis (2008) 14(3):310-7. doi:10.1002/ibd.20328
154. Moran GW, Pennock J, McLaughlin JT. Enteroendocrine cells in terminal ileal Crohn's disease. J Crohns Colitis (2012) 6(9):871-80. doi:10.1016/j.crohns.2012.01.013
155. Fishbein TM, Novitskiy G, Lough DM, Matsumoto C, Kaufman SS, Shetty K, et al. Rejection reversibly alters enteroendocrine cell renewal in the transplanted small intestine. Am J Transplant (2009) 9(7):1620-8. doi:10.1111/j.1600-6143.2009.02681.x
156. Friedrich M, Diegelmann J, Schauber J, Auernhammer CJ, Brand S. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunol (2015) 8(4):943-58. doi:10.1038/mi.2014.124
157. Chouliaras G, Panayotou I, Margoni D, Mantzou E, Pervanidou P, Manios Y, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn's disease and ulcerative colitis. Pediatr Res (2013) 74(4):420-6. doi:10.1038/pr.2013.114
158. Karrasch T, Obermeier F, Straub RH. Systemic metabolic signaling in acute and chronic gastrointestinal inflammation of inflammatory bowel diseases. Horm Metab Res (2014) 46(6):445-51. doi:10.1055/s-0034-1374587
159. Korkmaz H, Sahin F, Ipekci SH, Temel T, Kebapcilar L. Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease. Eur J Gastroenterol Hepatol (2014) 26(7):725-32. doi:10.1097/MEG.0000000000000104
160. Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition (2009) 25(2):172-81. doi:10.1016/j.nut.2008.07.020
161. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol (2007) 19(12):1070-4. doi:10.1097/MEG.0b013e3282f16251
162. Bregenzer N, Hartmann A, Strauch U, Schölmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis (2006) 12(1):53-6. doi:10.1097/01.MIB.0000195975.97673.f5
163. Moran GW, Leslie FC, McLaughlin JT. Crohn's disease affecting the small bowel is associated with reduced appetite and elevated levels of circulating gut peptides. Clin Nutr (2013) 32(3):404-11. doi:10.1016/j.clnu.2012.08.024
164. Keller J, Binnewies U, Rösch M, Juul Holst J, Beglinger C, Andresen V, et al. Gastric emptying and disease activity in inflammatory bowel disease. Eur J Clin Invest (2015) 45:1234-42. doi:10.1111/eci.12542
165. Besterman HS, Mallinson CN, Modigliani R, Christofides ND, Pera A, Ponti V, et al. Gut hormones in inflammatory bowel disease. Scand J Gastroenterol (1983) 18(7):845-52. doi:10.3109/00365528309182104
166. El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med (1997) 242(5):413-9. doi:10.1046/j.1365-2796.1997.00237.x
167. Keller J, Beglinger C, Holst JJ, Andresen V, Layer P. Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol (2009) 297(5):G861-8. doi:10.1152/ajpgi.00145.2009
168. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol (2000) 278(4):R1057-63
169. Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH, Polak JM. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol (1987) 410(5):391-6. doi:10.1007/BF00712758
170. Moran GW, O'Neill C, Padfield P, McLaughlin JT. Dipeptidyl peptidase-4 expression is reduced in Crohn's disease. Regul Pept (2012) 177(1-3):40-5. doi:10.1016/j.regpep.2012.04.006
171. Mimura S, Ando T, Ishiguro K, Maeda O, Watanabe O, Ujihara M, et al. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. Scand J Gastroenterol (2013) 48(10):1152-9. doi:10.3109/00365521.2013.832366
172. Lee SJ, Lee J, Li KK, Holland D, Maughan H, Guttman DS, et al. Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology (2012) 153(3):1141-51. doi:10.1210/en.2011-1954
173. Qi KK, Wu J, Wan J, Men XM, Xu ZW. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis. Peptides (2014) 52:11-8. doi:10.1016/j.peptides.2013.11.012
174. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol (1999) 277(5 Pt 1):E937-47
175. Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg (2000) 35(6):847-51. doi:10.1053/jpsu.2000.6861
176. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol (1999) 276(1 Pt 1):G79-91
177. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG, Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis (2010) 16(6):962-73. doi:10.1002/ibd.21117
178. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut (2011) 60(7):902-14. doi:10.1136/gut.2010.218271
179. Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology (2012) 143(6):1473.e-81.e. doi:10.1053/j.gastro.2012.09.007
180. García-Martínez JM, Chocarro-Calvo A, Moya CM, García-Jiménez C. WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia (2009) 52(9):1913-24. doi:10.1007/s00125-009-1429-1
181. Gustafson B, Smith U. WNT signalling is both an inducer and effector of glucagon-like peptide-1. Diabetologia (2008) 51(10):1768-70. doi:10.1007/s00125-008-1109-6
182. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev (2005) 19(8):877-90. doi:10.1101/gad.1295405
183. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev (2007) 87(4):1409-39. doi:10.1152/physrev.00034.2006
184. Robertson MD, Livesey G, Morgan LM, Hampton SM, Mathers JC. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man. J Endocrinol (1999) 161(1):25-31. doi:10.1677/joe.0.1610025
185. Gledhill A, Hall PA, Cruse JP, Pollock DJ. Enteroendocrine cell hyperplasia, carcinoid tumours and adenocarcinoma in long-standing ulcerative colitis. Histopathology (1986) 10(5):501-8. doi:10.1111/j.1365-2559.1986.tb02501.x
186. Hormannsperger G, von Schillde MA, Haller D. Lactocepin as a protective microbial structure in the context of IBD. Gut Microbes (2013) 4(2):152-7. doi:10.4161/gmic.23444
187. Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J (2014) 13:60. doi:10.1186/1475-2891-13-60
188. Delzenne NM, Cani PD, Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. J Nutr (2007) 137(11 Suppl):2547S-51S
189. Nogueira AM, Barbosa AJ. Immunocytochemical study of intestinal endocrine cells in germ-free mice. Eur J Histochem (1994) 38(3):213-8
190. Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm (2014) 2014:162021. doi:10.1155/2014/162021
191. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol (2011) 17(12):1519-28. doi:10.3748/wjg.v17.i12
192. Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J, et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene (2014) 537(1):85-92. doi:10.1016/j.gene.2013.11.081
193. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem (2013) 288(35):25088-97. doi:10.1074/jbc.M113.452516
194. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes (2011) 60(11):2775-86. doi:10.2337/db11-0227
195. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol (2004) 54(Pt 5):1469-76. doi:10.1099/ijs.0.02873-0
196. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A (2013) 110(22):9066-71. doi:10.1073/pnas.1219451110
197. Hofmann AF, Borgstroem B. The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. J Clin Invest (1964) 43:247-57. doi:10.1172/JCI104909
198. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 30(11):570-80. doi:10.1016/j.tips.2009.08.001
199. Li T, Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol (2015) 31(2):159-65. doi:10.1097/MOG.0000000000000156
200. Han JL, Lin HL. Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. World J Gastroenterol (2014) 20(47):17737-45. doi:10.3748/wjg.v20.i47.17737
201. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem (2004) 279(22):23158-65. doi:10.1074/jbc.M314322200
202. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab (2013) 17(2):225-35. doi:10.1016/j.cmet.2013.01.003
203. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol (2006) 188(5):1979-86. doi:10.1128/JB.188.5.1979-1986.2006
204. Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol (2014) 171(2):R47-65. doi:10.1530/EJE-14-0154
205. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep (2014) 14(5):482. doi:10.1007/s11892-014-0482-4
206. Chen S, Okahara F, Osaki N, Shimotoyodome A. Increased GIP signaling induces adipose inflammation via a HIF-1alpha-dependent pathway and impairs insulin sensitivity in mice. Am J Physiol Endocrinol Metab (2015) 308(5):E414-25. doi:10.1152/ajpendo.00418.2014
207. Gruber L, Kisling S, Lichti P, Martin FP, May S, Klingenspor M, et al. High fat diet accelerates pathogenesis of murine Crohn's disease-like ileitis independently of obesity. PLoS One (2013) 8(8):e71661. doi:10.1371/journal.pone.0071661
208. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab (2004) 287(1):E182-7. doi:10.1152/ajpendo.00189.2003
209. Zietek T, Rath E, Haller D, Daniel H. Intestinal organoids for assessing nutrient transport, sensing and incretin secretion. Sci Rep (2015) 5:16831. doi:10.1038/srep16831